Literature DB >> 18669465

Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy.

Johannes A Langendijk1, Patricia Doornaert, Irma M Verdonck-de Leeuw, Charles R Leemans, Neil K Aaronson, Ben J Slotman.   

Abstract

PURPOSE: To investigate the impact of treatment-related toxicity on health-related quality of life (HRQoL) among patients with head and neck squamous cell carcinoma treated with radiotherapy either alone or in combination with chemotherapy or surgery. PATIENTS AND METHODS: The study sample was composed of 425 disease-free patients. Toxicity was scored according to the European Organisation for Research and Treatment of Cancer (EORTC)/Radiation Therapy Oncology Group (RTOG) late radiation-induced morbidity scoring system. HRQoL was assessed using the EORTC Quality of Life Questionnaire C30. These assessments took place at 6, 12, 18, and 24 months after completion of radiotherapy. The analysis was performed using a multivariate analysis of variance.
RESULTS: Of the six RTOG scales investigated, two significantly affected self-reported HRQoL, salivary gland (RTOG(xerostomia)) and esophagus/pharynx (RTOG(swallowing)). Although RTOG(xerostomia) was reported most frequently, HRQoL was most affected by RTOG(swallowing), particularly in the first 18 months after completion of radiotherapy.
CONCLUSION: Late radiation-induced toxicity, particularly RTOG(swallowing) and RTOG(xerostomia), has a significant impact on the more general dimensions of HRQoL. These findings suggest that the development of new radiation-induced delivery techniques should not only focus on reduction of the dose to the salivary glands, but also on anatomic structures that are involved in swallowing.

Entities:  

Mesh:

Year:  2008        PMID: 18669465     DOI: 10.1200/JCO.2007.14.6647

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  187 in total

1.  Intensity-modulated radiotherapy for laryngeal and hypopharyngeal cancer: minimization of late dysphagia without jeopardizing tumor control.

Authors:  Anouchka Modesto; Anne Laprie; Laure Vieillevigne; Pierre Graff; Jérôme Sarini; Sébastien Vergez; Jean-Pierre Delord; Jean-Claude Farenc; Emmanuelle Vigarios; Thomas Filleron; Michel Rives
Journal:  Strahlenther Onkol       Date:  2014-11-01       Impact factor: 3.621

2.  Soft, fortified ice-cream for head and neck cancer patients: a useful first step in nutritional and swallowing difficulties associated with multi-modal management.

Authors:  Aaron Trinidade; Katrina Martinelli; Zenon Andreou; Prasad Kothari
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-09-21       Impact factor: 2.503

3.  Health-related quality of life in Japanese patients with metastatic renal cell carcinoma treated with sunitinib.

Authors:  Hideaki Miyake; Ken-Ichi Harada; Yuji Kusuda; Masato Fujisawa
Journal:  Int J Clin Oncol       Date:  2011-12-27       Impact factor: 3.402

4.  [Multimodal laryngeal preservation: current data-based opinion].

Authors:  A Dietz; A Boehm; G Wichmann; D Niederwieser; S Dietzsch; M Fuchs
Journal:  HNO       Date:  2012-01       Impact factor: 1.284

5.  Depression, fatigue, and health-related quality of life in head and neck cancer patients: a prospective pilot study.

Authors:  Namie Okino Sawada; Juliana Maria de Paula; Helena Megumi Sonobe; Marcia Maria Fontão Zago; Giselle Patricia Guerrero; Adriana Cristina Nicolussi
Journal:  Support Care Cancer       Date:  2012-11       Impact factor: 3.603

6.  Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy.

Authors:  David L Schwartz; Katherine Hutcheson; Denise Barringer; Susan L Tucker; Merrill Kies; F Christopher Holsinger; K Kian Ang; William H Morrison; David I Rosenthal; Adam S Garden; Lei Dong; Jan S Lewin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-06-18       Impact factor: 7.038

7.  Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation.

Authors:  Steven J Frank; Pierre Blanchard; J Jack Lee; Erich M Sturgis; Merrill S Kies; Mitchell Machtay; Bhadrasain Vikram; Adam S Garden; David I Rosenthal; G Brandon Gunn; C David Fuller; Katherine Hutcheson; Stephen Lai; Paul M Busse; Nancy Y Lee; Alexander Lin; Robert L Foote
Journal:  Semin Radiat Oncol       Date:  2018-04       Impact factor: 5.934

Review 8.  A systematic review of salivary gland hypofunction and xerostomia induced by cancer therapies: management strategies and economic impact.

Authors:  S B Jensen; A M L Pedersen; A Vissink; E Andersen; C G Brown; A N Davies; J Dutilh; J S Fulton; L Jankovic; N N F Lopes; A L S Mello; L V Muniz; C A Murdoch-Kinch; R G Nair; J J Napeñas; A Nogueira-Rodrigues; D Saunders; B Stirling; I von Bültzingslöwen; D S Weikel; L S Elting; F K L Spijkervet; M T Brennan
Journal:  Support Care Cancer       Date:  2010-03-25       Impact factor: 3.603

9.  Organ sparing and clinical outcome with step-and-shoot IMRT for head and neck cancer: a mono-institutional experience.

Authors:  Rosario Mazzola; Giuseppe Ferrera; Filippo Alongi; Mariella Mannino; Boris Abbate; Teresa Cucchiara; Giuseppina Iacoviello; Francesco Sciumè; Gioacchino Di Paola; Manuela Federico; Livio Blasi; Antonio Lo Casto; Roberto Lagalla; Domenico Messana
Journal:  Radiol Med       Date:  2015-02-07       Impact factor: 3.469

Review 10.  Clinical management of salivary gland hypofunction and xerostomia in head-and-neck cancer patients: successes and barriers.

Authors:  Arjan Vissink; James B Mitchell; Bruce J Baum; Kirsten H Limesand; Siri Beier Jensen; Philip C Fox; Linda S Elting; Johannes A Langendijk; Robert P Coppes; Mary E Reyland
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-11-15       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.